TrialAnnals of oncology : official journal of the European Society for Medical Oncology2023

IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.

M Burotto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.